Shopping Cart 0
Cart Subtotal
USD 0

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375

Details

Veloxis Pharmaceuticals AS (VELO)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company lead product is ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the company's proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company sells ENVARSUS XR to government agencies, specialty pharmacies, managed healthcare organizations, wholesalers and retail customers across the US, Europe and worldwide. Veloxis is headquartered in Copenhagen, Denmark.

Veloxis Pharmaceuticals AS Key Recent Developments

Aug 08,2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019

Jul 22,2019: Veloxis revises outlook for 2019 based on strong performance

May 06,2019: Veloxis Pharmaceuticals announces financial results for the first three months of 2019

Feb 27,2019: Veloxis Pharmaceuticals releases annual report for 2018

Jan 03,2019: Mark Hensley promoted to Chief Commercial Officer of Veloxis Pharmaceuticals

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Veloxis Pharmaceuticals AS-Key Facts

Veloxis Pharmaceuticals AS-Key Employees

Veloxis Pharmaceuticals AS-Key Employee Biographies

Veloxis Pharmaceuticals AS-Major Products and Services

Veloxis Pharmaceuticals AS-History

Veloxis Pharmaceuticals AS-Company Statement

Veloxis Pharmaceuticals AS-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Veloxis Pharmaceuticals AS-Business Description

Geographical Segment: Europe

Performance

Geographical Segment: Rest of the world (RoW)

Performance

Geographical Segment: United States

Performance

Veloxis Pharmaceuticals AS-Corporate Strategy

Veloxis Pharmaceuticals AS-SWOT Analysis

SWOT Analysis-Overview

Veloxis Pharmaceuticals AS-Strengths

Veloxis Pharmaceuticals AS-Weaknesses

Veloxis Pharmaceuticals AS-Opportunities

Veloxis Pharmaceuticals AS-Threats

Veloxis Pharmaceuticals AS-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Recent Deals Summary

Section 5-Company's Recent Developments

Aug 08, 2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019

Jul 22, 2019: Veloxis revises outlook for 2019 based on strong performance

May 06, 2019: Veloxis Pharmaceuticals announces financial results for the first three months of 2019

Feb 27, 2019: Veloxis Pharmaceuticals releases annual report for 2018

Jan 03, 2019: Mark Hensley promoted to Chief Commercial Officer of Veloxis Pharmaceuticals

Nov 14, 2018: Veloxis Pharmaceuticals announces financial results for the first nine months of 2018

Oct 31, 2018: Ira Duarte promoted to chief financial officer of Veloxis Pharmaceuticals

Sep 24, 2018: Morten Marott Steps Down as Chief Financial Officer of Veloxis Pharmaceuticals

Aug 13, 2018: Veloxis Pharmaceuticals announces financial results for the first six months of 2018

May 14, 2018: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Veloxis Pharmaceuticals AS, Performance Chart (2014-2018)

Veloxis Pharmaceuticals AS, Ratio Charts

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Veloxis Pharmaceuticals AS, Key Facts

Veloxis Pharmaceuticals AS, Key Employees

Veloxis Pharmaceuticals AS, Key Employee Biographies

Veloxis Pharmaceuticals AS, Major Products and Services

Veloxis Pharmaceuticals AS, History

Veloxis Pharmaceuticals AS, Subsidiaries

Veloxis Pharmaceuticals AS, Key Competitors

Veloxis Pharmaceuticals AS, Ratios based on current share price

Veloxis Pharmaceuticals AS, Annual Ratios

Veloxis Pharmaceuticals AS, Annual Ratios (Cont...1)

Veloxis Pharmaceuticals AS, Interim Ratios

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Veloxis Pharmaceuticals AS, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Roche a/s

Metkinen Oy

Quantum Genomics SA

Sanofi-aventis Canada Inc

Novartis Pharmaceuticals UK Ltd

Genzyme Corp

Astellas Pharma A/S

Company Profile

Company Profile Title

Veloxis Pharmaceuticals AS (VELO)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company lead product is ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the company's proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company sells ENVARSUS XR to government agencies, specialty pharmacies, managed healthcare organizations, wholesalers and retail customers across the US, Europe and worldwide. Veloxis is headquartered in Copenhagen, Denmark.

Veloxis Pharmaceuticals AS Key Recent Developments

Aug 08,2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019

Jul 22,2019: Veloxis revises outlook for 2019 based on strong performance

May 06,2019: Veloxis Pharmaceuticals announces financial results for the first three months of 2019

Feb 27,2019: Veloxis Pharmaceuticals releases annual report for 2018

Jan 03,2019: Mark Hensley promoted to Chief Commercial Officer of Veloxis Pharmaceuticals

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Veloxis Pharmaceuticals AS-Key Facts

Veloxis Pharmaceuticals AS-Key Employees

Veloxis Pharmaceuticals AS-Key Employee Biographies

Veloxis Pharmaceuticals AS-Major Products and Services

Veloxis Pharmaceuticals AS-History

Veloxis Pharmaceuticals AS-Company Statement

Veloxis Pharmaceuticals AS-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Veloxis Pharmaceuticals AS-Business Description

Geographical Segment: Europe

Performance

Geographical Segment: Rest of the world (RoW)

Performance

Geographical Segment: United States

Performance

Veloxis Pharmaceuticals AS-Corporate Strategy

Veloxis Pharmaceuticals AS-SWOT Analysis

SWOT Analysis-Overview

Veloxis Pharmaceuticals AS-Strengths

Veloxis Pharmaceuticals AS-Weaknesses

Veloxis Pharmaceuticals AS-Opportunities

Veloxis Pharmaceuticals AS-Threats

Veloxis Pharmaceuticals AS-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Recent Deals Summary

Section 5-Company's Recent Developments

Aug 08, 2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019

Jul 22, 2019: Veloxis revises outlook for 2019 based on strong performance

May 06, 2019: Veloxis Pharmaceuticals announces financial results for the first three months of 2019

Feb 27, 2019: Veloxis Pharmaceuticals releases annual report for 2018

Jan 03, 2019: Mark Hensley promoted to Chief Commercial Officer of Veloxis Pharmaceuticals

Nov 14, 2018: Veloxis Pharmaceuticals announces financial results for the first nine months of 2018

Oct 31, 2018: Ira Duarte promoted to chief financial officer of Veloxis Pharmaceuticals

Sep 24, 2018: Morten Marott Steps Down as Chief Financial Officer of Veloxis Pharmaceuticals

Aug 13, 2018: Veloxis Pharmaceuticals announces financial results for the first six months of 2018

May 14, 2018: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Veloxis Pharmaceuticals AS, Performance Chart (2014-2018)

Veloxis Pharmaceuticals AS, Ratio Charts

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Veloxis Pharmaceuticals AS, Key Facts

Veloxis Pharmaceuticals AS, Key Employees

Veloxis Pharmaceuticals AS, Key Employee Biographies

Veloxis Pharmaceuticals AS, Major Products and Services

Veloxis Pharmaceuticals AS, History

Veloxis Pharmaceuticals AS, Subsidiaries

Veloxis Pharmaceuticals AS, Key Competitors

Veloxis Pharmaceuticals AS, Ratios based on current share price

Veloxis Pharmaceuticals AS, Annual Ratios

Veloxis Pharmaceuticals AS, Annual Ratios (Cont...1)

Veloxis Pharmaceuticals AS, Interim Ratios

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Veloxis Pharmaceuticals AS, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Veloxis Pharmaceuticals AS, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Roche a/s

Metkinen Oy

Quantum Genomics SA

Sanofi-aventis Canada Inc

Novartis Pharmaceuticals UK Ltd

Genzyme Corp

Astellas Pharma A/S